| __timestamp | Novo Nordisk A/S | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 26760000000 | 305409000 |
| Thursday, January 1, 2015 | 32169000000 | 377080000 |
| Friday, January 1, 2016 | 32339000000 | 432829000 |
| Sunday, January 1, 2017 | 32124000000 | 496079000 |
| Monday, January 1, 2018 | 33313000000 | 557616000 |
| Tuesday, January 1, 2019 | 35830000000 | 658498000 |
| Wednesday, January 1, 2020 | 36886000000 | 770456000 |
| Friday, January 1, 2021 | 41058000000 | 840100000 |
| Saturday, January 1, 2022 | 50684000000 | 944700000 |
| Sunday, January 1, 2023 | 61598000000 | 1136600000 |
| Monday, January 1, 2024 | 67377000000 | 1464300000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Novo Nordisk A/S and Vertex Pharmaceuticals Incorporated, two giants in the sector, have shown contrasting trends in their SG&A management from 2014 to 2023.
Novo Nordisk has seen a significant increase in SG&A expenses, rising by approximately 130% over the decade. This growth reflects their expansive global operations and strategic investments in marketing and administration. In contrast, Vertex Pharmaceuticals has maintained a more conservative growth in SG&A costs, increasing by about 270% over the same period. This suggests a more controlled approach, possibly due to their focused niche in the biotech sector.
Understanding these trends provides valuable insights into each company's operational strategies and financial health, offering a glimpse into their future trajectories.
Eli Lilly and Company and Vertex Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Johnson & Johnson
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Madrigal Pharmaceuticals, Inc.
Novo Nordisk A/S and Walgreens Boots Alliance, Inc.: SG&A Spending Patterns Compared
Novo Nordisk A/S vs Grifols, S.A.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or United Therapeutics Corporation
Vertex Pharmaceuticals Incorporated or Ascendis Pharma A/S: Who Manages SG&A Costs Better?
Vertex Pharmaceuticals Incorporated or Protagonist Therapeutics, Inc.: Who Manages SG&A Costs Better?
Vertex Pharmaceuticals Incorporated vs Wave Life Sciences Ltd.: SG&A Expense Trends